Trump FDA nominee deflects Sanders's push for universal healthcare endorsement at confirmation hearing

Dr. Heidi Overton, President Trump's pick to lead the FDA, refused to declare healthcare a "human right" during a tense Senate confirmation exchange with Sen. Bernie Sanders, and pointed instead to falling drug prices under Trump administration policies.

Sanders, the Vermont independent who ranks as the top Democrat on the Senate health committee, used his questioning time Thursday to press Overton on whether every American deserves guaranteed healthcare coverage. Overton, a physician who completed her residency at Johns Hopkins in Baltimore and previously worked with the America First Policy Institute, declined to answer with a simple yes or no. She told Sanders that access to healthcare is important and that she looks forward to carrying out the policies and responsibilities "vested from Congress" to the FDA.

That answer was not what Sanders wanted. He tried again, framing the question around international comparisons and mortality figures. Overton held her ground, steering the conversation toward prescription drug pricing data rather than broad ideological commitments about government-run medicine.

Sanders invoked Canada, Overton cited CPI data

The sharpest moment came when Sanders pointed north. He told the hearing room:

"I live 50 miles away from the Canadian border. Somehow, everybody in that country can go to a doctor."

Sanders argued that the United States stands alone among major nations in failing to guarantee healthcare and that "thousands die" because of lack of access and affordability. He did not cite a specific study or data source for that figure during the exchange.

Overton responded with numbers of her own. She told Sanders that 89 percent of branded drugs are now covered by agreements to lower prices for American consumers and credited the Trump administration's most-favored nation pricing policies for the shift. Then she offered a statistic that undercut Sanders's broader framing:

"The most-favored nation policies have dropped prices and, right now, CPI says that for the first time in 60 years, prescription drug prices have gone down by 3%."

Sanders was not buying it. He fired back that the decline might owe more to legislation Congress passed several years ago, though he did not name the specific bill. The exchange captured a familiar divide: Sanders demanding a sweeping philosophical concession, and the nominee answering with policy specifics that credited the current administration.

That divide is not unique to this hearing. Across the Democratic caucus, the commitment to Medicare for All has grown shakier even among members who once championed it. House Democratic leader Hakeem Jeffries backed away from the proposal after co-sponsoring it twice, a sign that the political ground has shifted beneath the single-payer cause Sanders has built his career around.

Overton would replace Makary after flavored-vape dispute

If confirmed, Overton would take over an agency that has already seen leadership turnover under Trump. Dr. Marty Makary resigned as FDA commissioner earlier this year after clashing with the administration over flavored vapes. The details of that disagreement were not spelled out during Thursday's hearing, but Makary's departure left the agency without a permanent head at a time when drug pricing, food safety, and regulatory reform remain front-burner issues.

Overton's background, medical residency at one of the country's top hospitals, followed by policy work at a Trump-aligned think tank, positions her as a nominee who shares the administration's priorities. Her refusal to wander into Sanders's universal-healthcare framing suggested she intends to keep the FDA focused on its statutory lane rather than wade into the broader entitlement debate.

Sanders, for his part, acknowledged the clock. He told the hearing he was "running out of time" and moved on, leaving the healthcare-as-a-right question unresolved. That outcome was predictable. Sanders has asked versions of the same question of nominees for years, and the answer from Republican-aligned witnesses has been consistent: talk about what the agency can do, not about remaking the entire system.

The broader progressive wing Sanders leads continues to fracture over strategy and alliances. Rep. Alexandria Ocasio-Cortez recently dismissed calls to distance herself from controversial allies, and DSA-backed candidates have scored primary upsets in Michigan, revealing a party still sorting out whether its future belongs to Sanders-style democratic socialists or to members willing to work within existing market structures.

Drug prices fell 3%, and both sides want credit

The most telling policy detail from Thursday's hearing was one both sides tried to claim. Prescription drug prices dropping 3 percent, the first decline in six decades, by Overton's account, is a concrete result that voters can feel at the pharmacy counter. Overton credited the administration's most-favored nation approach, which ties what American buyers pay to the lower prices negotiated by other countries. Sanders credited congressional legislation, without specifying which law he meant.

That credit fight matters more than the philosophical sparring. Whoever wins it shapes the 2026 midterm argument on healthcare costs. And the fact that Overton arrived at the hearing armed with the 89-percent and 3-percent figures suggests the administration plans to run hard on drug pricing as a tangible accomplishment, not on abstract promises of universal coverage.

Meanwhile, fractures inside the Senate Democratic caucus keep widening on issues well beyond healthcare. Sen. John Fetterman broke with his party to side with Trump on artificial intelligence policy, warning that American hesitation only benefits China. Sen. Elizabeth Warren broke with Sen. Schumer to back a progressive challenger in a Michigan Senate primary. Sanders may still command the hearing-room spotlight, but the coalition he needs to turn his healthcare vision into law keeps splintering in different directions.

Sanders can ask the question at every confirmation hearing from now until he retires. But as long as drug prices are falling and nominees show up with data instead of ideology, the answer will keep landing the same way, and the universal-healthcare dream will stay exactly where it has been for decades: in the speech, not in the statute.